Last updated on March 2019

3BNC117-LS First-in-Human Phase 1 Study


Brief description of study

This study is a phase 1, open label, dose-escalation study of the mAb 3BNC117-LS administered intravenously in HIV (human immunodeficiency virus)-uninfected individuals and HIV-infected individuals. The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single infusion of 3BNC117-LS in HIV-uninfected and HIV-infected individuals.

Detailed Study Description

The proposed study is a Phase 1, open label, dose escalation cohort study of 3BNC117-LS administered intravenously in HIV-uninfected and HIV-1 infected participants.

Study participants will be administered a single intravenous infusion of 3BNC117-LS at one of three increasing dose levels (3 mg/kg, 10 mg/kg and 30 mg/kg) and will be followed for 48 weeks after 3BNC117-LS administration.

This trial will enroll 15 to 30 participants into 5 study groups.

First, eligible participants will be enrolled in Group 1A (n=3-6; HIV-uninfected, 3 mg/kg) and participants will be administered 3BNC117-LS at least one day apart. No more than 2 participants in Group 1A will be administered 3BNC117-LS in a given week.

Enrollment in Group 1B (n=3-6; HIV-uninfected, 10 mg/kg) and Group 2B (n=3-6; HIV-infected on or off ART (antiretroviral therapy), 10 mg/kg) will begin after participants enrolled in Group 1A reach day 42 with 1 dose limiting toxicity (DLT: any adverse event of grade 3 or greater toxicity, if the study investigators recognize a probable or definite attribution to 3BNC117-LS). Participants will be administered 3BNC117-LS at least one day apart.

Enrollment in Group 1C (n=3-6; HIV-uninfected, 30 mg/kg) will begin after participants enrolled in Group 1B reach day 42 with 1 DLT. The first 3 participants enrolled in Group 1C will be administered 3BNC117-LS at least one day apart, and no more than 2 participants will be administered 3BNC117-LS in a given week. After the first 3 participants enrolled in Group 1C reach day 42 with 1 DLT, the remaining 3 participants will be enrolled, and administered 3BNC117-LS at least one day apart.

Enrollment in Group 2C (n=3-6; HIV-infected on or off ART, 30 mg/kg) will begin after participants enrolled in Group 2B reach day 42 with 1 DLT. The first 3 participants enrolled in Group 2C will be administered 3BNC117-LS at least one day apart. After the first 3 participants enrolled in Group 2C reach day 42 with 1 DLT, the remaining 3 participants will be enrolled, and administered 3BNC117-LS at least one day apart.

Following 3BNC117-LS infusion, study participants will return for safety assessments at weeks 1, 2 and 4 following infusion, then bi-monthly or monthly until the end of study follow up.

Serum samples for PK (pharmacokinetic) measurements will be collected before 3BNC117-LS infusion, at the end of the infusion, and at multiple time points during study follow up.

Samples will also be collected for measurement of HIV-1 plasma RNA levels before 3BNC117-LS infusion (screen, pre-infusion and day 0) and at all follow up visits in Groups 2B and 2C.

All participants will be followed for 48 weeks after 3BNC117-LS infusion.

Clinical Study Identifier: NCT03254277

Contact Investigators or Research Sites near you

Start Over

The Rockefeller University

New York, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.